Shijiazhuang Yiling Pharmaceutical Co Ltd SZSE:002603:
SAYS SUBSIDIARY RECEIVED NATIONAL MEDICAL PRODUCTS ADMINISTRATION'S APPROVAL FOR IRBESARTAN
Shijiazhuang Yiling Pharmaceutical Says Subsidiary's Irbesartan Approved
Shijiazhuang Yiling Pharmaceutical Co., Ltd. on 6ix
Earlier from Shijiazhuang Yiling Pharmaceutical
- Net profit rose 277.56% to ¥1.29 billion on 20.24% revenue growth, with robust cash flow
- Shijiazhuang Yiling Pharmaceutical Sees 2025 Net Profit 1.2-1.3 Billion Yuan
- Shijiazhuang Yiling Pharmaceutical Co: Net profit soared 80.33% to ¥1.00 billion despite a 7.82% revenue decline
- Yiling Pharmaceutical Q3 Net Profit Up 1264.6% Y/Y
- Shijiazhuang Yiling Pharmaceutical Co: Net profit rose 26% to ¥669 million despite a 12% revenue drop, with strong cash flow
Follow Shijiazhuang Yiling Pharmaceutical into a list and get an email when it puts out news.
Follow Shijiazhuang Yiling Pharmaceutical